TY - JOUR
T1 - Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment
AU - Zhou, X. Clare
AU - Dowdy, Sean C.
AU - Podratz, Karl C.
AU - Jiang, Shi Wen
PY - 2007/10
Y1 - 2007/10
N2 - Aberrant DNA methylation is an important molecular alteration commonly detected in various malignancies. Hypermethylation and expression silencing have been frequently found in multiple genes including those for steroid receptors, tumor suppressors, and DNA repair factors. Differential DNA methylation patterns are detected in type I and type II endometrial cancers, suggesting divergent epigenetic backgrounds and unique tumorigenic pathways. In this review, the implications of new findings in the field of epigenetics are discussed for endometrial cancer prevention, diagnosis, and treatment. DNA methylation-based assays may be explored as a useful adjunct diagnostic tool. Epigenetic modification reagents, including DNA methyltransferase and histone deacetylase inhibitors, when used alone or in combination with conventional chemotherapy, may be beneficial for endometrial cancer patients. Recent studies on epigenetic reactivation of the progesterone receptor provide a novel approach for re-sensitization of advanced, PR-negative endometrial cancers to progestational therapy.
AB - Aberrant DNA methylation is an important molecular alteration commonly detected in various malignancies. Hypermethylation and expression silencing have been frequently found in multiple genes including those for steroid receptors, tumor suppressors, and DNA repair factors. Differential DNA methylation patterns are detected in type I and type II endometrial cancers, suggesting divergent epigenetic backgrounds and unique tumorigenic pathways. In this review, the implications of new findings in the field of epigenetics are discussed for endometrial cancer prevention, diagnosis, and treatment. DNA methylation-based assays may be explored as a useful adjunct diagnostic tool. Epigenetic modification reagents, including DNA methyltransferase and histone deacetylase inhibitors, when used alone or in combination with conventional chemotherapy, may be beneficial for endometrial cancer patients. Recent studies on epigenetic reactivation of the progesterone receptor provide a novel approach for re-sensitization of advanced, PR-negative endometrial cancers to progestational therapy.
UR - http://www.scopus.com/inward/record.url?scp=34648843717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34648843717&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2007.06.019
DO - 10.1016/j.ygyno.2007.06.019
M3 - Review article
C2 - 17692907
AN - SCOPUS:34648843717
SN - 0090-8258
VL - 107
SP - 143
EP - 153
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -